Differences in glycemic trends due to reconstruction methods after proximal gastrectomy from the perspective of continuous glucose-monitoring
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Double-tract reconstruction after proximal gastrectomy increases hypoglycemia risk in gastric cancer patients. Esophagogastrostomy may offer better glycemic control, reducing glucose variability post-surgery.
Area Of Science
- Gastroenterology
- Endocrinology
- Surgical Oncology
Background
- Hypoglycemia prevention is a growing clinical concern.
- Proximal gastrectomy is a surgical procedure for gastric cancer.
- Glycemic variability impacts patient outcomes.
Purpose Of The Study
- To evaluate the impact of different reconstruction methods after proximal gastrectomy on glycemic variability.
- To assess postoperative hypoglycemia in non-diabetic patients with gastric cancer.
Main Methods
- Prospective observational study (April 2020 - March 2023).
- Utilized flash continuous glucose-monitoring (FCGM) for glycemic profiling.
- Monitored glucose trends for two weeks post-discharge.
Main Results
- Compared esophagogastrostomy (n=10) and double-tract reconstruction (n=10).
- Double-tract reconstruction showed significantly higher time below 70 mg/dL (p=0.049).
- Nocturnal hypoglycemia correlated with older age and double-tract reconstruction (p=0.025).
Conclusions
- Findings offer insights into reconstruction techniques following proximal gastrectomy.
- Highlights the association between double-tract reconstruction and increased hypoglycemia risk.
- Emphasizes the importance of assessing postoperative glycemic control.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...